COLUMBIA, SC --NOV 20-- SleepMed announces the appointment of Dr. Donald L. Schomer of Boston, MA to its Medical Advisory Panel. The panel is comprised of distinguished leaders in the field of sleep medicine and epilepsy and chaired by Dr. Richard Bogan of Columbia, SC, the chairman and co-founder of SleepMed. Other members of the Panel are Dr. Philip M. Becker of Dallas, TX, Dr. June M. Fry of Philadelphia, PA, Dr. Dennis L. Hill of Salisbury, NC, and Dr. Kingman P. Strohl of Cleveland, OH. Bogan explained, "The Panel's mission is to share its vast knowledge and experience by advising SleepMed's senior management team on the science, systems and solutions for the diagnosis and treatment of sleep disorders and epilepsy."
Dr. Schomer is Director of the Clinical Neurophysiology Lab and Chief of the Comprehensive Epilepsy Program at the Beth Israel Deaconess Medical Center in Boston. He is an Associate Professor of Neurology at the Harvard Medical School. He is a graduate of the University of Michigan Medical School and trained in Internal Medicine at Mary Imogene Bassett Hospital at Columbia University. He did his Neurology training and a Neurophysiology fellowship at McGill University in Montreal Quebec.
Dr. Schomer has served on numerous committees and journal review boards and is President-Elect of the American Clinical Neurophysiology Society. He is one of the original founders of DigiTrace Care Services, Inc. and served as its National Medical Director from its inception in 1991 until the company's merger in 1999. He now serves as SleepMed's National Medical Director for EEG services.
As the nation's leading sleep services and neurodiagnostic monitoring company, SleepMed performs 25,000 sleep studies and 17,000 patient days of ambulatory EEG monitoring each year at over 85 locations in 20 states. SleepMed's mission is to establish the first national brand in sleep services and maintain its strong leadership position in ambulatory EEG monitoring.
The Company's proprietary DigiTrace monitoring system is the gold standard in ambulatory EEG. This technology platform has also been clinically validated for unattended full PSG studies in patients' homes. The DigiTrace system is currently being used in a national clinical study by a major pharmaceutical firm to determine the effects of a pain drug on sleep architecture.
